

Beckman Coulter launches new immunoassay system for sepsis

21 March 2019 | News

Access PCT strengthens industry's most extensive portfolio of in-vitro diagnostic testing for sepsis identification and management



Beckman Coulter, a global leader in clinical diagnostics, has recently announced the launch of Access PCT assay, the latest addition to its extensive menu for the Access Family of Immunoassay Systems.

The state-of-the-art sensitivity and low-end precision of Access PCT assay combined with short incubation time, helps physicians assess the risk of patients progressing to severe sepsis or septic shock, helps physicians in the risk assessment of critically ill patients in danger of progression to severe sepsis or septic shock, with test results available in under 20 minutes.

The launch of Access PCT follows the recent release of the Early Sepsis Indicator, a unique hematological marker available on Beckman Coulter's DxH900 Hematology Analyzer as a part of the routine CBC with differential analysis.

The new Access PCT assay recently received CE mark certification and is available for use on the Access Family of Immunoassay Systems including the Access 2, UniCel DxI 600 and UniCel DxI 800.